[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.
Yu-Waye Chu, insider at Fate Therapeutics
Yu-Waye Chu Insider Alerts

Get notified the next time Yu-Waye Chu buys or sells Fate Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Yu-Waye Chu Insider Information

Dr. Yu-Waye (Wayne) Chu is Senior Vice President, Clinical Development at Fate Therapeutics, overseeing the company’s clinical development strategies. Prior to joining Fate, Wayne assumed roles of increasing responsibility in Product Development Oncology at Genentech since 2009, where he worked on the development of the HER2-directed antibody drug conjugate trastuzumab emtansine (Kadcyla). He joined the Early Clinical Development group in Genentech Research and Early Development (gRED) in 2011 where he led the early clinical development of molecules spanning multiple therapeutic platforms including antibody drug conjugates, checkpoint inhibitors, and immune cell bispecific antibodies, notably the development of polatuzumab vedotin (anti-CD79b antibody drug conjugate), tiragolumab (anti-TIGIT monoclonal antibody) and mosunetuzumab (CD20/CD3 bispecific antibody), and continued to lead the global development of mosunetuzumab in Product Development Oncology at Roche/Genentech. Dr. Chu conducted his clinical training in pediatric hematology-oncology at Johns Hopkins School of Medicine and the National Cancer Institute. His major clinical and research interests included hematopoietic stem cell transplantation for the treatment of pediatric cancers, and T-cell biology with a focus on T-cell development and maturation, T-cell homeostasis and immune reconstitution following stem cell transplant. Dr. Chu graduated cum laude with a B.A. in Molecular Biology from Princeton University, and earned his M.D. with Distinction in Research from the University of Rochester School of Medicine and Dentistry.

What is Yu-Waye Chu's net worth?

The estimated net worth of Yu-Waye Chu is at least $2.57 million as of April 16th, 2021. Dr. Chu owns 67,200 shares of Fate Therapeutics stock worth more than $2,573,760 as of January 20th. This net worth evaluation does not reflect any other assets that Dr. Chu may own. Learn More.

How do I contact Yu-Waye Chu?

The corporate mailing address for Dr. Chu and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]

Has Yu-Waye Chu been buying or selling shares of Fate Therapeutics?

Over the course of the past ninety days, Yu-Waye Chu has sold $192,342.00 in shares of Fate Therapeutics stock. Most recently, Yu-Waye Chu sold 3,965 shares of the business's stock in a transaction on Tuesday, January 11th. The shares were sold at an average price of $48.51, for a transaction totalling $192,342.15.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), Louis Petrillo (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO).

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 468,271 shares worth more than $32,473,718.77. The most recent insider tranaction occured on January, 11th when CFO Edward J Dulac III sold 1,770 shares worth more than $85,756.50. Insiders at Fate Therapeutics own 18.6 % of the company.

Information on this page was last updated on 1/11/2022.

Yu-Waye Chu Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2022Sell3,965$48.51$192,342.15View SEC Filing Icon  
12/10/2021Sell7,500$51.46$385,950.00View SEC Filing Icon  
4/16/2021Sell3,275$83.30$272,807.5067,200View SEC Filing Icon  
See Full Table

Yu-Waye Chu Buying and Selling Activity at Fate Therapeutics

This chart shows Yu-Waye Chu's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $38.30
Low: $37.97
High: $41.95

50 Day Range

MA: $52.93
Low: $38.30
High: $64.34

2 Week Range

Now: $38.30
Low: $37.97
High: $118.14

Volume

1,246,401 shs

Average Volume

1,386,200 shs

Market Capitalization

$3.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46
3 Cryptos to Buy for 2022
Is your crypto portfolio ready for 2022?

With Bitcoin hitting all-time highs, now is the time to reorient your crypto plays for the coming year.

That's why Luke Lango, InvestorPlace's resident crypto expert is releasing his latest calls… completely free.

You can get them in his latest report, "3 Cryptos to Beat Bitcoin."
Just click here to claim your copy today.